Skip to content
  1. Home/
  2. Latest news

Latest news

Could we be on our way to eliminating cancer for good?

What once seemed like an unattainable goal may soon be within our grasp. Learn how Johnson & Johnson is working toward its vision to create a world without cancer.

Johnson & Johnson named to Fortune‘s 2025 America’s Most Innovative Companies list

The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.

More from Johnson & Johnson

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

Meet two Johnson & Johnson nurse educators dedicated to teaching cancer care providers

Jennifer Huff and Jacqui Mellott are two of Johnson & Johnson’s oncology clinical educators—a team of 50 nurses who visit hospitals and infusion centers to help providers understand and stay up to date with treatments.

Careers

Looking for a career opportunity at Johnson & Johnson? Search our available jobs.

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

What is metastatic cancer?

The number of people living with this advanced form of cancer is on the rise. Learn how Johnson & Johnson is pioneering innovations to help patients live longer.

“The surgical devices I design help speed healing and save lives”

Candice Otrembiak’s work combines her love of science with her natural problem-solving skills. The result: high-tech devices that help make medical procedures more efficient for surgeons and safer for patients.

Press releases

Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer

Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse events, signaling human kallikrein 2 (KLK2) as a novel, highly specific target

Johnson & Johnson MedTech Announces New Clinical Data for the MONARCHTM Platform for Robotically-Assisted Bronchoscopy

Largest multi-center prospective robotically-assisted bronchoscopy (RAB) study to date contributes to cannon of scientific evidence and advances clinical understanding

Johnson & Johnson showcases latest advancements in cancer innovation with more than 70 clinical and real-world studies at ASCO and EHA

New CARVYKTI® data help shift the treatment paradigm in relapsed or refractory multiple myeloma with five-year progression-free survival rates Late-breaking AKEEGA® data selected for ASCO Press Program, showcasing prostate cancer leadership and potential in patients with HRR-altered mCSPC Early results from next-generation molecules for leukemia, lymphoma, multiple myeloma and prostate cancer showcase pipeline strength

Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL™ in the US, Redefining Image Clarity in 2D Intracardiac Imagingi

New ultrasound catheter delivers superior image quality,i,ii peak maneuverability and seamless CARTO™ 3 System integrationi, giving physicians improved visualizationii for added confidence during cardiac ablation procedures

More from Johnson & Johnson

What are clinical trials?

Behind every innovative medicine, treatment and therapy is a clinical trial. To help you understand them better, here’s a closer look at how they work.

Using your own cells to fight cancer

Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.